Zymeworks presents preclinical data on RAS-targeting drug conjugates
Tweet Send to a Friend
Zymeworks Inc. (NASDAQ: ZYME) announced six poster presentations featuring preclinical data from its antibody-drug conjugate programs at the American Association ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


